QR kód

Patient-Reported Outcomes From LIBRETTO-431: First-Line Selpercatinib Versus Chemotherapy With Pembrolizumab in RET Fusion-Positive NSCLC

Introduction: The benefit of first-line selpercatinib versus platinum-based chemotherapy with or without pembrolizumab in patients with advanced RET fusion-positive NSCLC has been previously reported. The patient-reported outcomes (PROs) from the LIBRETTO-431 trial presented here further support the...

Celý popis

Uloženo v:
Hlavní autoři: Caicun Zhou, MD, PhD, Silvia Novello, MD, PhD, Pilar Garrido, MD, PhD, Christophe Dooms, MD, PhD, Jorge Alatorre-Alexander, MD, Niels Reinmuth, MD, Gill Worthy, PhD, Kim Cocks, PhD, Justin Williams, PhD, Hongmei Han, MS, MApSt, Minji K. Uh, PhD, Nalin Payakachat, PhD, Adrienne M. Gilligan, PhD, Koichi Goto, MD, PhD
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2025-07-01
Edice:JTO Clinical and Research Reports
Témata:
Patient-reported outcomes (PROs)
Non–small cell lung cancer (NSCLC)
Selpercatinib
Patient-reported tolerability
On-line přístup:http://www.sciencedirect.com/science/article/pii/S266636432500030X
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky